K2 Therapeutics raises US$50M to build global biotech pipeline from Singapore

K2 Therapeutics, a Singapore-based biotechnology company, has successfully raised US$50 million in seed financing from MPM BioImpact to build a global biotech pipeline. The investment has enabled K2 to expand its pipeline to eight therapeutic programs, ranging from pre-clinical candidates to clinical-stage programs, with a focus on antibody-drug conjugates and T-cell engagers.

This funding round allows K2 to overcome the challenges of drug development by sourcing drug candidates internationally and advancing them through the difficult middle stage of biotech, from candidate selection to human proof-of-concept. The company's approach reflects a growing trend in biotech financing, where investors are increasingly backing teams that can source overlooked or underdeveloped science globally.

With a CEO like Ying Huang, who has extensive experience in both operating and capital markets, K2 is well-positioned to rapidly advance differentiated therapeutic candidates with the potential to address significant unmet medical needs. Among K2's notable programs are antibody-drug conjugates and T-cell engagers, both of which have attracted significant investor and pharmaceutical interest globally.